Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance

NCT01624246 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT01624246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01624246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance
Lead sponsor
Forest Laboratories
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2012
Completion date
March 31, 2013
Enrollment
12 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

augmented renal clearance (arc), systemic inflammatory response syndrome (sirs)